News | February 27, 2023
Pathway to Cures Appoints Investment Committee
Read More
Press Release | February 2, 2023
Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors
Read More
Press Release | February 1, 2023
Dr. Joseph E. Eid, Who Led Merck’s Pioneering Clinical Development of KEYTRUDA®, joins Dragonfly Therapeutics as President of R&D
Read More
Press Release | January 31, 2023
Carisma Therapeutics Appoints Leading Solid Tumor Immunotherapy Expert Padmanee Sharma, MD, PhD to Scientific Advisory Board
Read More
